Your search history is turned on.
Date: April 10, 2024 Jurisdictions: Alberta, British Columbia
Telo Genomics Receives Accreditation from College of American Pathologists Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that t...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that pa...
Date: February 27, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - CEO-52-109FV2 Template 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Christopher Ross, acting in the capacity of Chief Financial Officer of Telo Genomics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Telo G...
Microsoft Word - CEO-52-109FV2 Template 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Sabine Mai, acting in the capacity of Chief Executive Officer of Telo Genomics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Telo Genomic...
Managements Discussion and Analysis Telo Genomics Corp. For the three and six months ended December 31, 2023 and 2022 Telo Genomics Corp. Management Discussion and Analysis For the Three and Six Months Ended December 31, 2023 and 2022 2 For the Three and ...
1 Condensed Consolidated Interim Financial Statements (Expressed in Canadian Dollars) Telo Genomics Corp. For the Three and Six Months Ended December 31, 2023 and 2022 (unaudi...
Date: February 13, 2024 Jurisdictions: Alberta, British Columbia
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post- treated patients. The study is being con...
Date: January 30, 2024 Jurisdictions: Alberta, British Columbia
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnostics products in the USA. TH...
Date: January 12, 2024 Jurisdictions: Alberta, Quebec
Amend Report of Exempt Distribution Form 45-106F1 Form 45-106F1 Report of Exempt Distribution ITEM 1 REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. 2023 06 22 (YYYY-MM-DD) ITEM 2 PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whet...
Date: January 5, 2024 Jurisdictions: Alberta, British Columbia
{00036870:1} Form 52-109F1 AIF Certification of annual filings in connection with voluntarily filed AIF This certificate is being filed on the same date that Telo Genomics Corp. (the issuer) has voluntarily filed an AIF. I, Christopher Ross, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the AIF, annua...